Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorHintz, Mandy
dc.contributor.authorBilger, Angelika
dc.contributor.authorOehlke, Oliver
dc.contributor.authorGrosu, Anca L.
dc.date.accessioned2022-04-26T06:45:30Z
dc.date.available2022-04-26T06:45:30Z
dc.date.issued2018-03
dc.description.abstractBackground: It has been suggested to replace the diagnosis-specific graded prognostic assessment (DS-GPA, based on performance status and number of brain metastases) for patients with primary malignant melanoma with the new Melanoma-molGPA. The latter is a more complex assessment, which also includes BRAF mutation status, age and extracranial metastases. To test the performance of the Melanoma-molGPA, we performed a validation study of this new survival prediction tool.<p> <p>Methods: A retrospective analysis of patients treated at two different academic institutions was performed. The four-tiered MelanomamolGPA was calculated as suggested in the original study.<p> <p>Results: Median overall survival was 5.4 months (95% confidence interval: 3.1 - 7.7 months). Median survival in the four prognostic classes was 2.1, 7.8, 11.8, and 18.0 months, respectively. The 1-year survival rates were 3%, 25%, 43%, and 80%, respectively. The difference between the Kaplan-Meier curves was significant (P = 0.0001, log-rank test).<p> <p>Conclusions: The present survival outcomes support the use of the Melanoma-molGPA. However, survival was better in each of the four groups in the original study. Possible reasons include lead-time bias and different treatment policies.en_US
dc.identifier.citationNieder C, Hintz M, Bilger A, Oehlke O, Grosu AL. Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).. Journal of Clinical Medicine Research. 2018;10(3):178-181en_US
dc.identifier.cristinIDFRIDAID 1674434
dc.identifier.doi10.14740/jocmr3248w
dc.identifier.issn1918-3003
dc.identifier.issn1918-3011
dc.identifier.urihttps://hdl.handle.net/10037/24880
dc.language.isoengen_US
dc.publisherElmer Pressen_US
dc.relation.journalJournal of Clinical Medicine Research
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2018 The Author(s)en_US
dc.titleValidation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).en_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record